Objective: To evaluate dietary intake and its relationship to lipid parameters in HIV-infected patients with metabolic abnormalities.
Introduction
Highly active antiretroviral therapy (HAART) has resulted in improvement in the long-term survival of HIV-infected patients [1] . However, the use of HAART is associated with metabolic complications such as dyslipidemia, insulin resistance, and altered fat distribution [2, 3] . Furthermore, these metabolic complications associated with HAART have been linked to an increased risk of myocardial infarction and cardiovascular disease [4] [5] [6] [7] .
In non-HIV-infected individuals, the impact of dietary saturated fat and cholesterol intake on serum lipids and subsequent development of cardiovascular disease is well established [8, 9] . In contrast, the degree to which HIVinfected patients consume dietary fat and cholesterol, the composition of the fat intake, and the relationship to serum lipid levels are relatively unknown. Several earlier small-scale studies in HIV-infected individuals have not demonstrated any significant relationship between saturated fat intake and serum lipid levels [10] [11] [12] . Furthermore, these studies did not compare the dietary intake of HIV-infected patients with metabolic abnormalities in the era of HAART to that of communitysampled controls in the context of established dietary guidelines. We therefore compared dietary intake in this population of HIV-infected patients with that of control individuals, using the 2005 United States Department of Agriculture (USDA) Recommended Dietary Guidelines, and assessed the relationship between dietary fat intake and HIV-related dyslipidemia.
Methods
Patients and controls Data on macronutrient intake were prospectively collected from 1998-2005 in 356 HIV-infected patients participating in metabolic studies at the Massachusetts General Hospital (MGH) and 162 HIV-negative individuals simultaneously recruited from the community as controls for these studies [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . HIV-infected patients with known wasting or evaluated for studies of AIDS wasting were not included in the analysis. HIV-infected patients aged 18-60 years were recruited from newspaper advertisement, community and referral-based practices. Patients could not be directly referred into the study by providers. For patients receiving antiretroviral therapy (ART), a stable regimen for a minimum of 6 weeks prior to evaluation was required. Patients were excluded if they had a history of diabetes mellitus; were receiving concurrent therapy with insulin, antidiabetic agents, glucocorticoids, growth hormone, supraphysiologic testosterone replacement, or anabolic steroids; were current substance abusers; had a major opportunistic infection within the 6 weeks prior to the study; or were pregnant or breast-feeding within the past year. The HIV-negative controls were recruited through hospital and local advertisements using many of the same community newspapers used to recruit HIV-infected individuals. The HIV-negative controls were required to have no history of diabetes mellitus. Other criteria, including age, medication use and reproductive status were similar between the HIV and non-HIV groups. For both HIV-infected and control groups, baseline data were obtained before any intervention. If individuals participated in more than one study, only data from the initial study were used. Collection of nutrient intake was approved by the institutional review board at MGH as well as at MIT (Massachusetts Institute of Technology), and all participants provided informed consent.
Protocol
All participants were studied after an overnight fast of 12 h. Each individual had a complete medical history, including documentation of all prior antiretrovirals and starting date for current antiretroviral regimen. Height and weight were measured as well as circumference of the hip and waist at the level of the umbilicus to calculate the waist-to-hip ratio (WHR). Individuals were categorized as having lipodystrophy based on WHR and evidence of fat redistribution as previously described [14] .
Individuals underwent total-body dual-energy X-ray absorptiometry (DEXA) with the use of the Hologic QDR-4500A scanner (Hologic Inc., Waltham, Massachusetts, USA) to determine total body fat as well as regional body fat measurements [28] . Cross-sectional abdominal computed tomography (CT) scans were performed as described by Borkan et al. to assess distribution of subcutaneous and visceral abdominal fat (SAT and VAT, respectively) [29] . Resting energy expenditure (REE) and respiratory quotient (RQ) were measured for 20 min by indirect calorimetry (Deltatrac or Vmax29, Sensormedics, Yorba Linda, California, USA) after the participants had been resting for 30 min. They also received a standard 75-g oral glucose tolerance test (OGTT).
Collection of nutrient intake data (including alcohol intake) was obtained via 4-day food records (3 weekdays and 1 weekend day) in 320 HIV-infected individuals and 108 controls and via 24-h food recall in an additional 36 HIV-infected individuals and 54 controls. For the 4-day food records, participants were instructed by trained dietitians to record completely all food and drink consumed. Incomplete records were then addressed by direct questioning. Individuals who were assessed using 24-h recall were asked both open-ended and closedended questions to determine dietary intake. Food models, cups, and measuring tools were used to aid in visualization and quantification of portion sizes. Nutrient calculations for energy intake, macronutrient, and alcohol consumption were performed with the Minnesota Nutrition Data System software (Nutrition Coordinating Center of the University of Minnesota, Minneapolis, Minnesota, USA).
Participants provided data regarding their home address, including zip code. Zip code information was compared with median income from the 2000 US Census data to provide an estimate of socio-economic status [30] . Participants were then stratified into quartiles based on median income. Insurance status (private, public, or other) was also determined to assess socio-economic status.
Laboratory methods
Complete blood count, CD4 cell count, HIV viral load, and fasting concentrations of glucose, insulin, cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were determined by methods described elsewhere [14] .
Statistical analysis
Data are expressed as mean AE standard deviation except where indicated. P values were derived from a mixed effects analysis of variance (ANOVA) model to determine differences between HIV and control participants adjusting for potential random effects of individual studies into which patients were recruited. We then further adjusted these P values for age, race, gender, body mass index (BMI), insurance status, and income quartile to determine statistically significant differences between HIV-infected patients and controls in the mixed effects ANOVA model, and performed a sensitivity analysis, determining the effects of insurance status on the modeling. The effects of time (expressed as calendar year of enrollment) on fat intake were also assessed in the modeling. BMI was not included in the adjustment of body composition parameters. Method of dietary assessment (24-h food recall vs. 4-day food record) was also added to the model as a covariate when analyzing macronutrient data. Use of lipid-lowering medications was adjusted for when analyzing serum lipid levels as well as macronutrient data. The analysis was also repeated including metabolic syndrome as a covariate in the model. The gender effects on fat intake in HIV-infected and non-HIV-infected individuals were examined using the multiple logistic regression models which were adjusted for age, race, gender, BMI, insurance status, use of lipid-lowering agents, method of dietary assessment, and income quartile. The event of interest in each logistic regression model was the fat intake above dietary fat guidelines.
Among HIV-infected patients, the change in dietary consumption over time (expressed as calendar year of enrollment) was assessed using a bivariate linear fit model with P values derived from univariate regression analyses. The effects of insurance status, lipodystrophy characterization, or protease inhibitor use on dietary fat intake among HIV-infected patients were determined by ANOVA.
In HIV-infected patients, a least squares multiple regression model was used to evaluate the relationship between dietary intake and metabolic parameters, with adjustment for age, gender, BMI, race, protease inhibitor (PI) use, alcohol consumption, total fiber intake, and impaired glucose tolerance (IGT)/diabetes in the model. We included time (expressed as calendar year of enrollment) in this model to assess whether time altered the relationship between dietary fat intake and lipid parameters. We also examined whether use of lipidlowering drugs altered the relationship between dietary fat intake and lipid parameters by including use of lipid-lowering therapy in the model. The study had 80% power to detect a difference of 4 g/day in saturated fat between the HIV and control groups, based on a twosided t test, alpha ¼ 0.05 and SD of 15 g/day. The minimum detectable statistical effect size was 26.7% of the SD. All statistical analyses were performed using SAS JMP software, version 5.0.1 (SAS Institute, Cary, North Carolina, USA).
Results
Three hundred and fifty-six HIV-infected patients (197 men, 159 women) and 162 non-HIV-infected controls (73 men, 89 women) were evaluated. There were no statistically significant differences between the two groups in terms of age, gender, race and income quartile. The mean duration of HIV illness was 8.5 AE 4.8 years. 88.8% of the HIV-infected individuals were receiving ART, of whom 66.8% were receiving PIs and 93.2% were receiving nucleoside reverse transcriptase inhibitors (NRTIs). The majority (72.5%) of HIV-infected individuals were categorized as having lipodystrophy (Table 1) . Table 2 and Fig. 1a and b. There was no statistically significant difference in total caloric intake between the two groups. Compared to controls, HIV-infected patients consumed a greater amount of total dietary fat (P < 0.05), saturated fat (P ¼ 0.006) and cholesterol (P ¼ 0.006) as well as a greater percentage of calories from saturated fat (P ¼ 0.002) and from trans fat (P ¼ 0.02).
Dietary intake Dietary macronutrient intake for HIV-infected patients and non-HIV-infected controls is presented in
Using the 2005 USDA Recommended Dietary Guidelines for total fat, saturated fat (< 10% of total caloric intake), and cholesterol (< 300 mg/day), we determined the percentage of HIV-infected patients and non-HIVinfected controls exceeding these recommendations, as an indicator of poor dietary habits [31] . Although these guidelines recommended total fat intake to be 20-35% of total caloric intake, we chose a value of < 35% for consistency. A significantly higher percentage of HIVinfected patients compared to controls were above these guidelines for saturated fat (76.0 vs. 60.9%, P ¼ 0.003) and cholesterol intakes (49.7 vs. 37.9%, P ¼ 0.04) ( Fig. 1c ).
The effects of HIV status on dietary fat intake parameters were not substantially altered by the addition of insurance status into the models. Similarly, no significant differences in fat consumption were seen between HIV-infected individuals with private insurance versus those with 1594 AIDS 2007, Vol 21 No 12 public insurance, indicating that insurance status did not have a significant effect on dietary fat consumption among HIV-infected participants in this study (data not shown).
There were no statistically significant differences in dietary carbohydrate, protein, mono-unsaturated fat, and polyunsaturated fat intakes between the two groups ( Fig. 1a and b ). Fiber intake (P ¼ 0.03) and alcohol consumption (P ¼ 0.005) were significantly lower in HIV-infected patients compared to controls ( Table 2) .
Since dietary intake could be influenced by changes over time, a time trend analysis was undertaken, in which dietary macronutrient intake was compared to time (expressed as calendar year), using a bivariate linear fit model. Among HIV-infected patients, the percentage of calories derived from total fat (r 2 ¼ 0.01, P ¼ 0.03) as well as from polyunsaturated fat (r 2 ¼ 0.02, P ¼ 0.006) increased linearly from 1997-2005, whereas the percentage intake from saturated fat and trans fat did not change with time. No statistically significant changes were seen in the primary endpoints when time was included as a covariate in our ANOVA mixed model. The usage of lipid-lowering drugs did not change significantly among HIV-infected individuals with time, and was included as a covariate in the ANOVA model used to examine dietary differences between HIV-infected and HIV-uninfected participants.
The effect of gender on the percentage of participants exceeding the USDA Recommended Dietary Guidelines was also examined. Only cholesterol intake was significantly affected by gender since a greater percentage of men than women in the HIV-infected population exceeded guidelines for cholesterol intake (Table 3) .
Metabolic, body composition, and energy parameters
HIV-infected individuals demonstrated higher total cholesterol (P ¼ 0.003), higher triglyceride (P < 0.0001), and lower HDL (P < 0.0001) levels than controls (Table 4 ). BMI and waist circumference were not different between HIV-infected and control groups, but hip circumference was lower and WHR higher among HIV-infected than control individuals. Significant differences in VAT and SAT were not seen in the HIV-infected compared to control participants, but HIV-infected patients demonstrated an increase in VAT/SAT, trunk to extremity ratio, and a decrease in total extremity fat. Fasting glucose levels were not different between the HIV-infected and control Fig. 1 (continued) for age, race, gender, BMI, insurance status, use of lipidlowering agents, method of dietary assessment, and income quartile, with each study assigned a random effect. zbased on the USDA Dietary Guidelines for Americans 2005 [31] . To convert mg/dl to mmol/l for total cholesterol and HDL, multiply by 0.0259; for triglycerides, multiply by 0.0113; for glucose, multiply by 0.0555; and to convert mIU/ml to pmol/l for insulin, multiply by 6.945.
In terms of energy metabolism, HIV-infected participants demonstrated higher absolute REE values (P < 0.0001), higher REE adjusted for fat-free mass (P < 0.0001), and lower RQ (P ¼ 0.02) when compared to controls ( Table 4) .
Relationship of dietary intake to serum lipid levels in HIV-infected patients
A multiple regression model was used to assess the contribution of dietary fat (g/day), saturated fat (g/day), trans fat (g/day), and cholesterol (mg/day) intakes to serum lipid levels, controlling for age, race, gender, BMI, PI use, alcohol consumption, total fiber intake, and IGT/ diabetes among the HIV-infected individuals. Saturated fat was significantly associated with triglyceride level [triglyceride level increased 8.7 mg/dl (parameter estimate) per gram of increased saturated fat intake, P ¼ 0.005], whereas total fat intake was inversely associated with triglyceride level [triglyceride level decreased 3.0 mg/dl (parameter estimate) per gram of increased total fat intake, P ¼ 0.02]. These relationships between saturated fat or total fat and triglyceride levels were not significantly altered when use of lipidlowering medications was entered into the model. There were no significant associations between dietary saturated fat, total fat, trans fat, or cholesterol intake and total cholesterol or HDL (Table 5 ).
Saturated fat and total fat still remained significantly associated with triglyceride level, even when time was entered into the model, indicating that although there were slight differences in dietary intake (specifically, in percentage of calories derived from total fat and polyunsaturated fat) over time, there was no significant effect of time on the association between saturated fat or total fat and triglyceride levels among HIV-infected individuals (data not shown).
Use of PI was not shown to be significantly associated with hypertriglyceridemia among our HIV-infected population. Importantly, no significant differences in fat intake were seen between HIV-infected patients receiving and not receiving PIs as well as between those with lipodystrophy and those without (data not shown).
Discussion
Metabolic complications, including dyslipidemia occur commonly among HIV-infected patients, and may contribute to increased CVD in this population [3, 4] . Given the potential significance of these metabolic complications, and the limited information regarding the relationship to dietary composition in the HIV-infected population, we prospectively evaluated the composition of dietary fat intake of HIV-infected individuals with metabolic abnormalities and compared these data to that of community-derived controls, using the 2005 USDA Recommended Dietary Guidelines. We also determined the relationship between dietary fat intake and dyslipidemia in this group of HIV-infected patients.
The HIV-infected patients in our study consumed a greater amount of total dietary fat, saturated fat, and Parameter estimate derived from least squares multiple regression modeling assessing the relationship of total fat, saturated fat, cholesterol, and trans-fat to serum lipid levels after controlling for age, gender, BMI, race, protease inhibitor use, alcohol consumption, total fiber intake, and impaired glucose tolerance/diabetes. b P value for parameter estimate derived from least squares multiple regression modeling assessing the relationship of total fat, saturated fat, cholesterol, and trans-fat to serum lipid levels after controlling for age, gender, BMI, race, protease inhibitor use, alcohol consumption, total fiber intake, and impaired glucose tolerance/diabetes. cholesterol as well as a greater percentage of calories from trans fat and from saturated fat. More importantly, a higher percentage of HIV-infected patients compared with controls exceeded the established 2005 USDA Recommended Dietary Guidelines for saturated fat and cholesterol. In particular, among HIV-infected patients, saturated fat intake directly correlated with hypertriglyceridemia whereas total fat intake inversely correlated with hypertriglyceridemia. These highly significant associations between saturated fat or total fat and serum lipid levels in HIV-infected patients in our study were seen even after controlling for PI use and major factors known to influence lipid levels, including gender, alcohol use, fiber intake, diabetes/IGT, BMI, age, and race.
The reasons for increased dietary fat consumption among our HIV-infected population were not formally assessed in this study and may be multifactorial. Our group as well as others have demonstrated an increased REE adjusted for fat-free mass among HIV-infected individuals in comparison with controls [33] . Increased dietary fat consumption among HIV-infected individuals with metabolic abnormalities may be a form of calorie-dense compensation for increased energy expenditure. The dietary fat consumption could also be centrally mediated through the effects of HIV itself or HAART on satiety/ hunger centers or peripherally mediated through alterations in taste perception. It is also possible that dietary assessment and advice may have been overlooked in this population.
Among HIV-infected patients, there was no significant effect of time on percentage of calories derived from saturated fat, but instead a small increase in the percentage of calories derived from polyunsaturated fat, leading to an increase in percentage of calories from total fat with time. Increased consumption of 'good fats' such as polyunsaturated fat has been advocated by the NCEP/ATP III guidelines for non-HIV-infected individuals with metabolic syndrome and hyperlipidemia [32] , but those dietary guidelines do also recommend total fat and saturated fat restriction. Thus, although recognition of metabolic syndrome and lipodystrophy among HIVinfected patients is increasing, the application of dietary guidelines to this population is only partially heeded.
The need for greater emphasis on saturated fat reduction in addition to increases in 'good fat' consumption is required.
Only a few prior studies have specifically examined dietary fat intake and its relation to serum lipid levels in HIV-infected patients [10] [11] [12] . Moreover, the inverse relationship between total fat intake and serum triglyceride levels has been previously reported in non-HIVinfected individuals but not in HIV-infected patients [8, 34] . In contrast, the percentage of energy from trans fat was significantly higher in HIV-infected patients, but did not correlate with serum lipid levels in our study. Nonetheless, it is important to recognize that increased trans fat intake may increase low-density lipoprotein (LDL) : HDL ratios and lipoprotein (a) levels, and increase the risk of atherosclerosis [35, 36] . Total fiber intake was lower in HIV-infected patients compared to controls, suggesting a lack of dietary variety in the form of fruits, vegetables, and legumes. Increased fiber intake (particularly soluble fiber) has been associated with a lower risk of cardiovascular disease [37, 38] .
In non-HIV-infected individuals, dietary intervention focusing on saturated fat restriction led to a decrease of 2-20% in triglyceride and 1-15% in total cholesterol levels [39] [40] [41] . In small clinical trials of dietary intervention in HIV-infected patients, similar reductions in total cholesterol (4-11%) and triglyceride levels (12-23%) have been achieved [42] [43] [44] . Based on our data, an increment of 1 g/day in saturated fat intake is associated with a statistically and clinically significant 8.7 mg/dl increase in triglyceride levels in HIV-infected patients with metabolic abnormalities. Thus, if the mean saturated fat intake of our HIV-infected individuals could be decreased from the observed level of 31 g/day shown in this study (representing 12% of total caloric intake) to 25 g/day (< 10% total caloric intake), this 6 g reduction in daily saturated fat intake would potentially result in a significant 52 mg/dl decrease in serum triglyceride levels. The mean serum triglyceride level among the HIVinfected patients in our study was 230 mg/dl, with a prevalence of hypertriglyceridemia similar to that of the DAD study [4] . Therefore a 6 g reduction in saturated fat would correspond to a 23% decrease in serum triglyceride levels, similar to published effects of dietary intervention trials in HIV-infected patients [42] [43] [44] .
Since we were evaluating dietary intake in HIV-infected individuals with metabolic abnormalities, we simultaneously recruited community-derived, non-HIV-infected controls with metabolic abnormalities as the appropriate comparator group. This control group was similar to the American population in terms of percentage meeting metabolic syndrome based on NCEP/ATP III criteria (22 vs. 24%, our controls vs. American population) as well as percentage of calories derived from saturated fat intake [45] [46] [47] [48] . The control population in our study often failed to meet the 2005 USDA Recommended Dietary Guidelines for total fat, saturated fat, and cholesterol, but demonstrated less saturated fat, total fat and cholesterol intake than the HIV group.
HIV-infected patients in our study demonstrated higher REE adjusted for fat-free mass and lower RQs, the latter implying a higher oxidation of lipids relative to that of carbohydrates. This occurred in the context of increased intake of dietary fats. Increased fat oxidation has been shown to occur as an adaptation to high fat diets in non-HIV-infected individuals [49, 50] . Our findings could possibly be explained by futile triglyceride/fatty acid cycling, in which there is a primary defect in adipocyte hormone-sensitive lipase, causing accelerated lipolysis, excess free fatty acid (FFA) flux, and increased hepatic production of very-low density lipoproteins (VLDL) in the fasted state. The increased FFA transit and VLDL formation are thought to result in increased energy expenditure whereas the increased FFA levels may promote lipid oxidation by mass action [51, 52] . These mechanisms may contribute to hypertriglyceridemia in HIV-infected patients.
There are limitations to our study. This convenience sample was chosen specifically to assess dietary intake among HIV-infected patients with metabolic abnormalities and a significant proportion was classified as having lipodystrophy. These results cannot, therefore, be generalized to the larger group of HIV-infected patients without metabolic abnormalities nor to HIV-infected patients with wasting or under-nutrition. Patients were not followed longitudinally over time to determine the relationship between changes in dietary intake and dyslipidemia. The method of dietary food assessment was primarily by prospective 4-day food record, but 17% of participants were assessed using 24-h food recall. We did, however, control for the method of dietary assessment in our analysis and still demonstrated significant findings. Despite these limitations, our findings of increased saturated fat intake in HIV-infected patients with metabolic abnormalities using a standardized reference guideline, e.g. the 2005 USDA Recommended Dietary Guidelines, and the independent strong association of saturated fat intake to hypertriglyceridemia point to a critical role for dietary intervention in this important subset of HIV-infected patients with increased cardiovascular risk.
In conclusion, we investigated dietary intake in and relationship to lipid parameters in HIV-infected patients. The anthropometric and biochemical features of the HIV-infected patients in our study are consistent with the altered metabolic phenotype seen in a high proportion of HIV-infected individuals in the era of HAART. Our study demonstrates that this specific subset of HIVinfected individuals consumes a more 'atherogenesispromoting' diet compared to community-sampled controls and a significantly greater percentage of these HIVinfected patients than community-sampled controls exceeded the 2005 USDA Recommended Dietary Guidelines for saturated fat and cholesterol. Importantly, saturated fat intake correlated directly and total fat correlated inversely with hypertriglyceridemia in these HIV-infected patients. Thus, based on these findings, the primary goal of dietary intervention in HIV-infected patients with metabolic abnormalities should be reduction in saturated fat, rather than an excessive reduction in total fat. Careful assessment of dietary intake and more aggressive dietary intervention may prove to be beneficial to the prevention of cardiovascular disease in this population of patients.
